These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28130691)

  • 21. Review of the role of NICE in promoting the adoption of innovative cardiac technologies.
    Groves PH; Pomfrett C; Marlow M
    Heart; 2018 Nov; 104(22):1817-1822. PubMed ID: 29773657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The normative grounds for NICE decision-making: a narrative cross-disciplinary review of empirical studies.
    Charlton V
    Health Econ Policy Law; 2022 Oct; 17(4):444-470. PubMed ID: 35293306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using health outcomes data to inform decision-making: government agency perspective.
    Taylor R
    Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decision making in NICE single technological appraisals: How does NICE incorporate patient perspectives?
    Hashem F; Calnan MW; Brown PR
    Health Expect; 2018 Feb; 21(1):128-137. PubMed ID: 28686809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
    Dakin HA; Devlin NJ; Odeyemi IA
    Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prioritizing health technologies in a Primary Care Trust.
    Wilson E; Sussex J; Macleod C; Fordham R
    J Health Serv Res Policy; 2007 Apr; 12(2):80-5. PubMed ID: 17407656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ethics of grandfather clauses in healthcare resource allocation.
    Wester G; Gibson Rand LZ; Lu C; Sheehan M
    Bioethics; 2021 Feb; 35(2):151-160. PubMed ID: 33043477
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NICE and Fair? Health Technology Assessment Policy Under the UK's National Institute for Health and Care Excellence, 1999-2018.
    Charlton V
    Health Care Anal; 2020 Sep; 28(3):193-227. PubMed ID: 31325000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?
    Sculpher M; Palmer S
    Pharmacoeconomics; 2020 Mar; 38(3):247-257. PubMed ID: 31930460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
    Bryan S; Williams I; McIver S
    Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of UK primary care databases in health technology assessments carried out by the National Institute for health and care excellence (NICE).
    Leahy TP; Ramagopalan S; Sammon C
    BMC Health Serv Res; 2020 Jul; 20(1):675. PubMed ID: 32698805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of national agencies in the managed introduction of new drugs for arthritis.
    Simister K
    Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i38-40. PubMed ID: 11053085
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of Economic Submissions to NICE Medical Technologies Evaluation Programme.
    Alshreef A; Jenks M; Green W; Dixon S
    Appl Health Econ Health Policy; 2016 Dec; 14(6):623-634. PubMed ID: 27480537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Devices, Diagnostics and Digital Technologies: A Review of NICE Medical Technologies Guidance.
    Crispi F; Naci H; Barkauskaite E; Osipenko L; Mossialos E
    Appl Health Econ Health Policy; 2019 Apr; 17(2):189-211. PubMed ID: 30367349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. It's not evidence, it's insight: bringing patients' perspectives into health technology appraisal at NICE.
    Staley K; Doherty C
    Res Involv Engagem; 2016; 2():4. PubMed ID: 29062505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
    Schaefer R; Schlander M
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
    [No Abstract]   [Full Text] [Related]  

  • 40. A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM FOR DEVICES: THE FIRST FIVE YEARS.
    Campbell B; Dobson L; Higgins J; Dillon B; Marlow M; Pomfrett C
    Int J Technol Assess Health Care; 2017 Jan; 33(1):19-24. PubMed ID: 28502278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.